<DOC>
	<DOCNO>NCT01588353</DOCNO>
	<brief_summary>To investigate efficacy safety AK160 patient Dupuytren 's Contracture . To determine plasma concentration first injection AK160 patient Dupuytren 's Contracture .</brief_summary>
	<brief_title>Collagenase Option Reduction Dupuytren 's Contracture Japan</brief_title>
	<detailed_description />
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>At least 20 year old write informed consent obtain . Having diagnosis Dupuytren 's contracture flexion contracture due palpable cord least 1 nonthumb finger ( 20° 100° MP joint 20° 80° PIP joint ) . Positive tabletop test result ( i.e. , simultaneously place affect finger palm table ) . Voluntary write informed consent obtain . Patients meet follow criterion exclude : Is pregnant , may pregnant , wish become could become pregnant study ( i.e. , unless acceptable contraception use , patient sterilize , patient postmenopausal [ menstrual period least 12 month without medical cause ] ) , breastfeed . Has coexist chronic disease hand could impact assessment ( muscular disease , neurological disease , neuromuscular disease ) . Has receive another investigational product 30 few day first injection investigational product . Has undergone aponeurectomy , aponeurotomy , needle aponeurotomy/fasciotomy , verapamil/interferon injection , another Dupuytren 's Contracture treatment primary joint 90 few day first injection investigational product . Is allergic collagenase excipients AK160 . Has take tetracycline derivative minocycline doxycycline 14 few day first injection investigational product . Has receive collagenase product 30 few day first injection investigational product . Is currently take take , 7 few day first injection investigational product , anticoagulant antiplatelet drug ( ≤150 mg/day aspirin ) . Has suffer recent stroke , hemorrhage , disease affect hand . Has serious disease unsuited study . Receiving treatment malignancy . History drug alcohol addiction within past 5 year history drug alcohol abuse within past year . Has receive previously investigational product ( AK160 , AA4500 , XIAFLEX® , XIAPEX® ) . Otherwise find ineligible subject investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AK160 , collagenase clostridium histolyticum</keyword>
</DOC>